MedPath

Intensive Combo Chemo With Autologous BM Rescue for Metastatic Breast Cancer

Phase 2
Completed
Conditions
Metastatic Breast Cancer
Interventions
Procedure: High-dose chemotherapy
Registration Number
NCT00584766
Lead Sponsor
University of Oklahoma
Brief Summary

To determine the therapeutic efficacy of high-dose cyclophosphamide and BCNU with autologous bone marrow transplantation after initial tumor cytoreduction for patients with receptor-negative metastatic breast carcinoma and to determine the optimal timing of CyBCNU-ABMT after initial development of metastatic breast carcinoma

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
21
Inclusion Criteria
  • breast carcinoma at first clinical evidence of metastatic disease
  • must have measurable disease by physical exam, x-ray, or scan
  • Age < or equal to 55
  • performance status 0-2
Read More
Exclusion Criteria
  • can't have had more than one prior chemotherapy regimen
  • can't have had concurrent hormonal therapy
  • no brain metastases
  • no previous pelvic radiation
  • no history of another malignancy
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
1High-dose chemotherapy-
Primary Outcome Measures
NameTimeMethod
Quality of maximal response; time to initial disease progression; and overall survivalundetermined
Secondary Outcome Measures
NameTimeMethod
to determine the optimal timing of CyBCNU-ABMT after initial development of metastatic breast cancerundetermined

Trial Locations

Locations (1)

University of Oklahoma Health Sciences Center

🇺🇸

Oklahoma City, Oklahoma, United States

© Copyright 2025. All Rights Reserved by MedPath